Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

December 31, 2003

Study Completion Date

February 28, 2006

Conditions
Hormone Resistant Prostate CancerMetastatic Prostate Cancer
Interventions
DRUG

docetaxel

35mg/m² on day 2 and 9 (21days in a cycle)

DRUG

estramustine

140mg caps x3 bid from day 1to 5 and day 8 to 12 of each cycle

DRUG

prednisone

2x5 mg a day

Trial Locations (19)

1040

Parc Léopold, Brussels

1050

Hôpitaux IRIS Sud, Brussels

1200

Cliniques Universitaires St luc, Brussels

1210

CHR Luxembourg, Luxembourg

1340

St Pierre, Ottignies

2930

Az klina, Brasschaat

4000

St Joseph, Liège

4700

Sint Nilolaus, Eupen

5000

clinique Sainte Elisabeth, Namur

5004

Clinique Saint Luc, Bouge

Clinique Universitaire de Mt Godinne, Yvoir

6000

Notre Dame et Reine Fabiola, Charleroi

Clinique St Joseph, Gilly

6041

Notre Dame de Grâce, Gosselies

7000

CHU Ambroise paré, Mons

7100

CH Jolimont Lobbes, La Louvière

7300

CHR Warquignies, Boussu

7331

RHMS louis caty, Baudour

7500

Notre Dame, Tournai

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

OTHER

NCT00541281 - Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer | Biotech Hunter | Biotech Hunter